Identification and Characterization of IMD-0354 as a Glutamine Carrier Protein Inhibitor in Melanoma [0.03%]
黑色素瘤中识别和表征IMD-0354作为谷氨酰胺载体蛋白抑制剂
Yongmei Feng,Gaurav Pathria,Susanne Heynen-Genel et al.
Yongmei Feng et al.
A key hallmark of cancer, altered metabolism, is central to cancer pathogenesis and therapy resistance. Robust glutamine metabolism is among cellular processes regulating tumor progression and responsiveness to therapy in a number of cancer...
Preclinical Assessment of AMG 596, a Bispecific T-cell Engager (BiTE) Immunotherapy Targeting the Tumor-specific Antigen EGFRvIII [0.03%]
靶向肿瘤特异性抗原EGFRvIII的双特异T细胞接头(BiTE)免疫疗法AMG 596的临床前评估
Alexander Sternjak,Fei Lee,Oliver Thomas et al.
Alexander Sternjak et al.
AMG 596 is a bispecific T-cell engager (BiTE) immuno-oncology therapy in clinical development for treatment of glioblastoma multiforme (GBM), the most common primary brain tumor in adults with limited therapeutic options. AMG 596 is compose...
Robust Antitumor Activity and Low Cytokine Production by Novel Humanized Anti-CD19 CAR T Cells [0.03%]
一种新型人源化抗CD19嵌合抗原受体T细胞具有良好的抗肿瘤活性和较低的细胞因子产生水平
Alka Dwivedi,Atharva Karulkar,Sarbari Ghosh et al.
Alka Dwivedi et al.
Recent studies have described the remarkable clinical outcome of anti-CD19 chimeric antigen receptor (CAR) T cells in treating B-cell malignancies. However, over 50% of patients develop life-threatening toxicities associated with cytokine r...
PP2A-activating Drugs Enhance FLT3 Inhibitor Efficacy through AKT Inhibition-Dependent GSK-3β-Mediated c-Myc and Pim-1 Proteasomal Degradation [0.03%]
PP2A激活药物通过AKT抑制依赖性GSK-3β介导的c-MYC和PIM-1蛋白酶体降解增强FLT3抑制剂疗效
Mario Scarpa,Prerna Singh,Christopher M Bailey et al.
Mario Scarpa et al.
Fms-like tyrosine-like kinase 3 internal tandem duplication (FLT3-ITD) is present in acute myeloid leukemia (AML) in 30% of patients and is associated with short disease-free survival. FLT3 inhibitor efficacy is limited and transient but ma...
V-ATPase Inhibition Decreases Mutant Androgen Receptor Activity in Castrate-resistant Prostate Cancer [0.03%]
V-ATP酶抑制可降低雄激素受体突变型活性以治疗去势抵抗性前列腺癌
Bradleigh Whitton,Haruko Okamoto,Matthew Rose-Zerilli et al.
Bradleigh Whitton et al.
Prostate cancer is critically dependent on androgen receptor (AR) signaling. Despite initial responsiveness to androgen deprivation, most patients with advanced prostate cancer subsequently progress to a clinically aggressive castrate-resis...
Rapid Resistance of FGFR-driven Gastric Cancers to Regorafenib and Targeted FGFR Inhibitors can be Overcome by Parallel Inhibition of MEK [0.03%]
雷罗拉非尼和靶向成纤维细胞生长因子受体抑制剂对FGFR驱动型胃癌的快速耐药性可通过平行抑制MEK来克服
David K Lau,Ian Y Luk,Laura J Jenkins et al.
David K Lau et al.
Amplification or overexpression of the FGFR family of receptor tyrosine kinases occurs in a significant proportion of gastric cancers. Regorafenib is a multikinase inhibitor of angiogenic and oncogenic kinases, including FGFR, which showed ...
Randomized Controlled Trial
Molecular cancer therapeutics. 2021 Apr;20(4):704-715. DOI:10.1158/1535-7163.MCT-20-0836 2021
Correction: MALAT1 is Associated with Poor Response to Oxaliplatin-based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2 [0.03%]
MALAT1与奥沙利铂为基础的化疗反应不良相关并通过EZH2促进抗药性（勘误）
Peilong Li,Xin Zhang,Haiyan Wang et al.
Peilong Li et al.
Published Erratum
Molecular cancer therapeutics. 2021 Feb;20(2):451. DOI:10.1158/1535-7163.MCT-20-1028 2021
Correction: Combined Inhibition of NEDD8-activating Enzyme and mTOR Suppresses NF2 Loss-driven Tumorigenesis [0.03%]
关于纠正：NEDD8激活酶和mTOR的联合抑制可抑制NF2丢失驱动的肿瘤发生
Jonathan Cooper,Qingwen Xu,Lu Zhou et al.
Jonathan Cooper et al.
Published Erratum
Molecular cancer therapeutics. 2021 Feb;20(2):450. DOI:10.1158/1535-7163.MCT-20-1027 2021
Molecular Targeting of RRM2, NF-κB, and Mutant TP53 for the Treatment of Triple-Negative Breast Cancer [0.03%]
靶向RRM2、NF-κB和突变TP53治疗三阴性乳腺癌
Elizabeth A Wilson,Nahid Sultana,Khyati N Shah et al.
Elizabeth A Wilson et al.
Doxorubicin and other anthracycline derivatives are frequently used as part of the adjuvant chemotherapy regimen for triple-negative breast cancer (TNBC). Although effective, doxorubicin is known for its off-target and toxic side effect pro...
Anti-LYPD1/CD3 T-Cell-Dependent Bispecific Antibody for the Treatment of Ovarian Cancer [0.03%]
抗LYPD1/CD3T细胞依赖性双特异性抗体治疗卵巢癌
Amy A Lo,Jennifer Johnston,Ji Li et al.
Amy A Lo et al.
Ovarian cancer is a diverse class of tumors with very few effective treatment options and suboptimal response rates in early clinical studies using immunotherapies. Here we describe LY6/PLAUR domain containing 1 (LYPD1) as a novel target fo...